Cytek Biosciences Acquires Flow Cytometry & Imaging Business From DiaSorin

  • DiaSorin's subsidiary Luminex Corporation will sell its Flow Cytometry & Imaging (FCI) business unit to Cytek Biosciences Inc CTKB. Deal terms were not disclosed.
  • The FCI business unit, acquired by Luminex in October 2018, is based on conventional flow cytometry and image-based flow cytometry instrumentation, providing insights into all facets of cellular phenotypes and morphology. 
  • The FCI business unit includes dedicated commercial, operations, R&D, and supporting personnel.
  • An existing installed base of more than 7,000 instruments will be under the Cytek umbrella following the acquisition, expanding the company's global commercial footprint.
  • The decision to sell the FCI business unit to Cytek aligns with the strategic priorities communicated to investors during the Capital Market Day in December 2021.
  • By adding first-to-market Amnis imaging flow cytometers to its robust lineup of cell analysis solutions, Cytek will be able to provide researchers and scientists with tools that combine high-resolution cell images with the speed, sensitivity, and phenotyping abilities of flow cytometry. 
  • Adding Guava flow cytometers will expand Cytek's core instrument offerings, adding cost-effective, entry-level, and personal instrument options to broaden the market and research areas it services.
  • Price Action: CTKB shares closed at $13.00 on Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: M&ANewsHealth CareSmall CapGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!